Lantheus Holdings, Inc. (NASDAQ:LNTH)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a note issued to investors on Friday, June 30th. They presently have a $18.00 price objective on the medical equipment provider’s stock. Jefferies Group LLC’s price objective points to a potential downside of 7.93% from the stock’s previous close.
Separately, Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $17.00 price objective on the stock in a research report on Thursday, May 4th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.60.
Lantheus Holdings (NASDAQ LNTH) traded up 3.44% during midday trading on Friday, reaching $19.55. 697,739 shares of the company traded hands. Lantheus Holdings has a 12 month low of $3.46 and a 12 month high of $20.40. The company’s 50-day moving average price is $17.25 and its 200 day moving average price is $13.53. The firm has a market capitalization of $728.49 million, a PE ratio of 32.80 and a beta of 0.93.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported $0.28 EPS for the quarter, topping the consensus estimate of $0.19 by $0.09. Lantheus Holdings had a net margin of 6.71% and a negative return on equity of 24.06%. The business had revenue of $81.36 million for the quarter, compared to analyst estimates of $77.75 million. On average, equities analysts anticipate that Lantheus Holdings will post $0.93 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/07/28/lantheus-holdings-inc-nasdaqlnth-receives-buy-rating-from-jefferies-group-llc-updated-updated-updated.html.
In other news, CEO Mary Anne Heino sold 10,000 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $15.39, for a total transaction of $153,900.00. Following the completion of the transaction, the chief executive officer now owns 602,468 shares of the company’s stock, valued at approximately $9,271,982.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Avista Capital Partners Gp, Ll sold 3,000,000 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $13.40, for a total transaction of $40,200,000.00. The disclosure for this sale can be found here. Insiders sold a total of 6,060,000 shares of company stock valued at $85,757,800 in the last three months. 2.30% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue bought a new position in Lantheus Holdings during the second quarter worth approximately $102,000. Municipal Employees Retirement System of Michigan bought a new position in Lantheus Holdings during the second quarter worth approximately $107,000. LS Investment Advisors LLC bought a new position in Lantheus Holdings during the second quarter worth approximately $112,000. Boothbay Fund Management LLC bought a new position in Lantheus Holdings during the fourth quarter worth approximately $128,000. Finally, Koch Industries Inc. bought a new position in Lantheus Holdings during the first quarter worth approximately $153,000. 64.83% of the stock is owned by institutional investors.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.